查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1622105

全球骨盆器官脱垂设备市场规模（按设备、应用、最终用户、地区、范围和预测）

Global Pelvic Organ Prolapse Devices Market Size By Device (Vaginal Pessary, Vaginal Mesh), By Application (Surgical Devices, Non-Surgical Devices), By End-User (Hospitals, Ambulatory Surgical Centers), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

骨盆腔器官脱垂设备的市场规模及预测

2022 年骨盆腔器官脱垂设备市场规模价值为 1.8536 亿美元，预计到 2030 年将达到 4.0512 亿美元，2023 年至 2030 年的复合年增长率为 4.12%。预计全球老年人口的增加和老龄女性人口中 POP 盛行率的上升将在未来几年推动骨盆器官脱垂设备市场的发展。全球骨盆器官脱垂设备市场报告对市场进行了全面的评估。它对关键细分市场、趋势、市场推动因素、阻碍因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

骨盆腔器官脱垂设备的全球市场定义

骨盆腔器官脱垂是由于骨盆区域支撑组织和肌肉变弱或鬆弛而发生的疾病。虽然这种疾病是可以治疗的，但骨盆器官脱垂装置旨在支撑骨盆器官，包括膀胱、子宫、小肠和部分阴道。

膀胱脱垂称为膀胱膨出。另一方面，小肠脱垂称为肠瘘。直肠脱垂称为直肠膨出。治疗骨盆腔器官脱垂的装置包括阴道托和阴道网片。这些仪器可用于手术和非手术器械等应用。骨盆腔器官脱垂设备的最终使用者包括医院、门诊手术中心等。

骨盆器官脱垂设备的全球市场概况

预计全球老年人口的增加和老龄女性人口中 POP 盛行率的上升将在未来几年推动骨盆器官脱垂设备市场的发展。除此之外，医疗保健支出在过去几十年中呈指数级增长，预计在预测期内也将呈现类似的趋势。这可能会在未来几年进一步促进骨盆腔器官脱垂设备的采用。根据世界卫生组织（WHO）发布的数据，骨盆腔器官脱垂是60-69岁女性最常见的疾病之一。约 37% 的 POP 患者年龄在 60 至 70 岁之间，超过一半的患者年龄超过 80 岁。

除此之外，骨盆器官脱垂修復治疗的技术进步和持续的研究开发以及对女性健康的认识的提高预计将在未来几年推动市场的发展。然而，某些限制和课题阻碍了市场的成长。缺乏科学的疗效和安全性、手术费用高、监管规范和标准复杂等因素在一定程度上限制了需求。

目录

第 1 章全球骨盆腔器官脱垂设备市场：简介
    市场概况
  • 研究范围
  • 先决条件

第 2 章执行摘要

第 3 章：经过验证的市场研究方法

  • 资料探勘
  • 验证
  • 第一次面试
  • 资料来源列表

第 4 章骨盆腔器官脱垂设备的全球市场前景
  • 概述
  • 市场动态
    • 驱动程式
    • 阻碍因素
    • 机会
  • 波特五力模型
  • 价值链分析

第5章全球骨盆腔器官脱垂设备市场（按设备）

  • 概述
  • 阴道栓剂
  • 阴道网片
第6章 全球骨盆腔器官脱垂设备市场（依应用）
  • 概述
  • 手术器械
  • 非手术设备

第7章 全球骨盆腔器官脱垂设备市场（依最终用户划分）

  • 概述
  • 医院
  • 门诊手术中心
  • 其他

第8章全球骨盆腔器官脱垂设备市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
    亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲国家
  • 中东和非洲
    • 阿拉伯联合大公国
    • 沙乌地阿拉伯
    • 南非
    • 其他中东和非洲地区

第 9 章全球骨盆腔器官脱垂设备市场：竞争格局
  • 概述
  • 各公司的市场排名
  • 主要发展策略

第10章 公司简介

  • Johnson & Johnson Services, Inc.
  • Coloplast Pty Ltd
  • Boston Scientific Corporation
  • CooperSurgical, Inc.
  • Dr. Arabin GmbH & Co. KG
  • Integra LifeSciences
  • Utah Medical Products, Inc.
  • Tic Med
  • Cleo
  • Shenzhen XFT Medical Limited
  • Sunmedix Co, Ltd.
  • Verity Medical Ltd
  • Neomedic
  • Medtronic
第 11 章：公司简介 - 主要发展
  • 产品发布/开发
  • 合併和收购
  • 业务扩展
  • 伙伴关係和合作关係

第 12 章附录

  • 相关研究
简介目录
Product Code: 15371

Pelvic Organ Prolapse Devices Market Size And Forecast

Pelvic Organ Prolapse Devices Market size was valued at USD 185.36 Million in 2022 and is projected to reach USD 405.12 Million By 2030 , growing at a CAGR of 4.12% from 2023 to 2030. The increasing global geriatric population and rising prevalence of POP in the aging female population are expected to drive the Pelvic Organ Prolapse Devices Market over the predicted years. The Global Pelvic Organ Prolapse Devices Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Pelvic Organ Prolapse Devices Market Definition

Pelvic organ prolapse is a condition that occurs after the supporting tissues and muscles become weak or loose in the pelvic region. Though the disease is treatable, pelvic organ prolapse devices are meant to provide support to the pelvic organs including the bladder, uterus, small intestine, and part of the vagina.

The prolapse of the bladder is known as a cystocele. While prolapse of the small bowel is known as enterocele. If there's a prolapse of the rectum, it is known as a rectocele. The devices for pelvic organ prolapse are vaginal pessary and vaginal mesh. They are used in applications including Surgical Devices and Non-Surgical Devices. End-users of pelvic organ prolapse devices are Hospitals, Ambulatory Surgical Centers, and Others.

Global Pelvic Organ Prolapse Devices Market Overview

The increasing global geriatric population and rising prevalence of POP in the aging female population are expected to drive the Pelvic Organ Prolapse Devices Market over the predicted years. Besides this, the healthcare expenditure growth has witnessed exponential growth over the past couple of decades and it is expected to show the similar trend over the forecasted period. This will further complement the adoption of pelvic organ prolapse devices over the upcoming years. As per the data published by the World Health Organization, Pelvic organ prolapse is one of the most common in disease found across the women aged 60 to 69. Around 37% of the POP patients are between 60-70 years of age and more than half of the patients are more than 80 years of age.

In addition to this, technical advancements and ngoing research and developments in pelvic organ prolapse repair treatments and the growing awareness about women's health expect a boost to the market in the coming years.The ongoing investments and frequent need for the respective treatments will create substantial opportunities over the forecasted period. However, there are certain restraints and challenges faced which can hinder market growth. Factors such as lack of scientific efficacy & safety, higher costs involved in surgeries, and complex regulatory norms and standards will restrict the demand to some extent.

Global Pelvic Organ Prolapse Devices Market: Segmentation Analysis

The Global Pelvic Organ Prolapse Devices Market is Segmented on the basis of Device, Application, End-User, and Geography.

Pelvic Organ Prolapse Devices Market, By Device

  • Vaginal Pessary
  • Vaginal Mesh

Based on Device, the market is bifurcated into Vaginal Pessary and Vaginal Mesh. The Vaginal Pessary segment is expected to hold the largest market share. The factors can be attributed to a higher preference for vaginal pessary as vaginal mesh causes bleeding which are one of the most commonly found instances wherein the pelvic organ prolapse devices are generally used.

Pelvic Organ Prolapse Devices Market, By Application

  • Surgical Devices
  • Non-Surgical Devices

Based on Application, the market is bifurcated into Surgical Devices and Non-Surgical Devices. Surgical Devices are predicted to hold the most significant CAGR in the forecasted period as surgical devices are more effective than non-surgical devices in the treatment of pelvic organ prolapse. On the other hand, non surgical devices will also significant share considering the varying needs in line with the symptoms and medication instances.

Pelvic Organ Prolapse Devices Market, By End-User

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Based on End-User, the market is bifurcated into Hospitals, Ambulatory Surgical Centers, and Others. Hospitals are anticipated to hold the largest market share. These factors can be credited to the higher rate of surgeries, growing treatment instances in the hospitals and lack of device applications in other clinics and ambulatory surgical centers. However, the ambulatory surgical centers will grow at the significant rate considering the rising awareness and ease of access.

Pelvic Organ Prolapse Devices Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Latin America
  • On the basis of regional analysis, the GlobalPelvic Organ Prolapse Devices Market is classified into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America led the Global Pelvic Organ Prolapse Devices Market in terms of growth, accounting for a sizable market share. The region is technologically advanced, and it was an early adoption of advanced healthcare technologies. Besides this, the strengthened healthcare infrastructure will further complement the market growth.

Key Players

  • The "Global Pelvic Organ Prolapse Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
  • Johnson & Johnson Services, Inc., Coloplast Pty Ltd, Boston Scientific Corporation, CooperSurgical, Inc., Dr. Arabin GmbH & Co. KG, Integra LifeSciences, , Utah Medical Products, Inc., Tic Med, Cleo, Shenzhen XFT Medical Limited, Sunmedix Co, Ltd., Verity Medical Ltd, Neomedic, and Medtronic among others.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In March 2020, the pelvic organ prolapse devices manufacturers, Fotofinder Zsystems Inc. has rebranded automated total body mapping systems as total body dermoscopy, allowing for immediate evaluation of dermoscopic structures of oles on full body photos.
  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as
  • Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Pelvic Organ Prolapse Devices market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in global Pelvic Organ Prolapse Devices market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY DEVICE

  • 5.1 Overview
  • 5.2 Vaginal Pessary
  • 5.3 Vaginal Mesh

6 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Surgical Devices
  • 6.3 Non-Surgical Devices

7 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Ambulatory Surgical Centers
  • 7.4 Others

8 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Rest of LATAM
  • 8.6 Middle East and Africa
    • 8.6.1 UAE
    • 8.6.2 Saudi Arabia
    • 8.6.3 South Africa
    • 8.6.4 Rest of the Middle East and Africa

9 GLOBAL PELVIC ORGAN PROLAPSE DEVICES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Johnson & Johnson Services, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Coloplast Pty Ltd
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Boston Scientific Corporation
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 CooperSurgical, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Dr. Arabin GmbH & Co. KG
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Integra LifeSciences
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Utah Medical Products, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Tic Med
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Cleo
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Shenzhen XFT Medical Limited
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Sunmedix Co, Ltd.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Verity Medical Ltd
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.13 Neomedic
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
    • 10.13.4 Key Developments
  • 10.14 Medtronic
    • 10.14.1 Overview
    • 10.14.2 Financial Performance
    • 10.14.3 Product Outlook
    • 10.14.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research